Other bisphosphonates like zoledronic acid and pamidronate are also used to manage bone complications in cancer patients. Additionally, newer agents like denosumab, a monoclonal antibody that inhibits RANKL, offer alternative therapeutic options. Each of these medications has its own set of benefits and risks, and the choice of treatment should be personalized.
